Status:
COMPLETED
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
Lead Sponsor:
Friends Research Institute, Inc.
Collaborating Sponsors:
University of California, Los Angeles
Conditions:
Amphetamine-Related Disorders
HIV
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This study seeks to decrease methamphetamine use and concomitant high-risk sexual behaviors among methamphetamine-using men who have sex with men (MSM) by combining a biomedical intervention with a be...
Detailed Description
At the baseline, all eligible participants underwent informed consent; completed baseline assessments; received rapid HIV testing; provided specimens for syphilis, gonorrhea and chlamydia testing; and...
Eligibility Criteria
Inclusion
- Individual must identify as a male who has sex with other men (MSM);
- At least 18 years of age;
- HIV negative serostatus on baseline rapid oral HIV antibody test;
- Self-reported methamphetamine use within the previous 72 hours and test positive for methamphetamine metabolites at baseline;
- Self-reported unprotected anal intercourse (either receptive or insertive) with an HIV-positive or status unknown partner within the previous 3 months;
- Self-reports no previous hypersensitivity to any of the components of Truvada (tenofovir disoproxil fumarate or emtricitabine);
- Willing to comply with study requirements (i.e., monitored urine testing three times per week, meet with physician within first week of enrollment, begin medication immediately following an unexpected high-risk sexual exposure, and contact the clinic and meet with physician within 92 hours of unexpected high-risk sexual exposure).
Exclusion
- Does not identify as a male who has sex with other men;
- Under 18 years of age;
- HIV positive, by self-report or as indicated by the results on the baseline rapid oral HIV antibody test;
- Self-reports any previous hypersensitivity to any of the components of Truvada;
- Has not used methamphetamine in the previous 72 hours and does not test positive for methamphetamine metabolites;
- Has not had unprotected anal intercourse with an HIV-positive or status unknown partner within the previous 3 months;
- Unwilling to comply with study requirements.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00856323
Start Date
January 1 2009
End Date
December 1 2010
Last Update
September 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Friends Community Center
Los Angeles, California, United States, 90028